News | November 15, 2022
Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
The company sees the business reaching $100mn
The company sees the business reaching $100mn
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Subscribe To Our Newsletter & Stay Updated
